Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma
Open Access
- 30 April 2013
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 108 (9) , 1801-1806
Abstract
Lenalidomide is an active immunomodulatory and antiproliferative agent in multiple myeloma. However, the molecular mechanisms driving these activities are not yet fully elucidated. Therefore, we investigated the modulation of the cytokine/growth factor patterns of myeloma cells under LEN treatment. Lenalidomide effect on myeloma cell proliferation was investigated in a myeloma cell line collection (n=23) by 3H-thymidine incorporation. Modulation of the cytokine/growth factor patterns of myeloma cells under LEN treatment was analysed by real-time quantitative PCR. Lenalidomide inhibits the proliferation of two-thirds of myeloma cell lines independently of their genetic background. We demonstrated that LEN increased TNF-α and IL-8 inflammatory cytokines and insulin-like growth factor-1 (IGF-1) growth factor in both sensitive and resistant myeloma cells to LEN. Lenalidomide favours a uniform TNF-α and IL-8 inflammatory and IGF-1 secretory profile of myeloma cells, an observation that raises important questions for therapeutic approaches incorporating the agent.Keywords
This publication has 17 references indexed in Scilit:
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour responseBritish Journal of Haematology, 2011
- Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting responseBritish Journal of Haematology, 2011
- Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implicationsBlood, 2011
- Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic MechanismCancer Research, 2009
- The role of the insulin-like growth factor 1 receptor axis in multiple myelomaArchives of Physiology and Biochemistry, 2009
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells.European Cytokine Network, 2007
- CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.2005